Cepheid Logo
Request Info
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}
{{initials}}
Main Menu
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Request Info
Request Info

Xpert® GBS LB XC

Order & Support
GBS LB XC computer generated depiction.
Detection of Group B Streptococcus with dual target with results within one hour

The Need

an ill woman listens to a physician
In the U.S., Group B Streptococcus (GBS) remains a leading cause of early onset neonatal sepsis. Rates of maternal colonization have not changed, but universal antenatal screening at 35–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early onset disease.1,2
  • Centers for Disease Control and American College of Obstetricians and Gynecologists practice guidelines recommend universal antepartum screening along with intrapartum where indicated based on risk
  • Risk based IAP exposes 65–85% of GBS-negative women with risk factors to antibiotics. This has been linked to emergence of resistant strains3
  • Up to 50% false negatives when testing with agar alone4
1 CDC. Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC, 2010. Nov 19, 2010 / 59(RR10);1-32.
2 ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol. 2011 Apr;117(4):1019-27.
3 Alfa MJ, et al. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus. J Clin Microbiol. 2010 Sep;48(9):3095-9.
4 Paolucci M, et al. How can the microbiologist help in diagnosing neonatal sepsis? Int J Pediatr. 2012;2012:120139
US-IVD. For In Vitro Diagnostic Use.

The Solution

a male and a female researchers scanning cepheid test cartridges
Cepheids GeneXpert® System*, with Xpert® GBS LB XC is a solution designed to support CDC‑recommended antenatal screening strategies, with results in approximately 42 minutes.
On-demand molecular testing — an ideal solution:
  • System designed with Early Assay Termination (EAT) with positive samples reported STAT
- As soon as positive sample is confirmed, software concludes test and reports immediately
  • Moderately complex testing with minimal hands-on time
- Testing can be performed in the clinical laboratory environment following enrichment
- Provides an automated molecular testing workflow for antenatal screening
- Random access ensures any test on the menu can be run anytime, without the need to batch run

The Impact

a smiling female doctor attends an elderly woman
The Xpert GBS LB XC test, performed on Cepheid's GeneXpert systems, delivers an elegant, simple and streamlined solution.
A molecular in vitro diagnostic, Xpert GBS LB XC is designed for use in the clinical lab. It allows users to perform three simple steps and the GeneXpert does the rest.
  • An automated molecular test with minimal hands‑on steps
  • Delivers results in as early as 27 minutes with early assay termination.
  • Fast accurate NAAT results
  • Moderate complexity

Connect To Better Outcomes

Request Info

Insights

Get More Insights